Similarly, Li J et al.(Li et al., 2021), Li SS et al. (Li S. S et al., 2020), Luo et al. (Luo et al., 2020), and Song et al.(Song et al., 2021) were also constructed multiple genes (including PLOD2) prognostic model, but all lacked tumor immune-related analysis or only had comparisons of different immune cell classifications. The gene discussed is PLOD2; the disease is neoplasm.